Zuellig Pharma acquired the Zam-Buk and Vapex brands from Bayer, expanding its consumer healthcare portfolio and market presence across Asia.
This acquisition allows Zuellig Pharma to enhance its consumer healthcare offerings in the APAC region, tapping into established brands with significant market presence. It signifies a strategic move to bolster its position in a growing market segment, potentially leading to increased accessibility of these products for consumers across various Asian countries and strengthening Zuellig Pharma's overall market share in consumer health.
Zuellig Pharma acquired Zam-Buk and Vapex brands from Bayer.
The acquisition strengthens Zuellig Pharma's consumer healthcare portfolio.
This move aims to expand market presence and product offerings in Asia.
The acquisition directly impacts the APAC region by expanding Zuellig Pharma's consumer healthcare portfolio with well-known brands, aiming to improve product accessibility and market penetration across multiple Asian markets.
This move aims to expand market presence and product offerings in Asia.
It signifies a strategic growth initiative in the consumer health segment.
Sign in to save notes on signals.
Sign In